Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Limited Benefit of Nivo/Ipi in Patients With Intermediate- or Poor-Risk mRCC With Symptomatic Disease
  2. Tumor Stage and Substage Predict Cancer-Specific Mortality After Nephrectomy for Nonmetastatic RCC
  3. Cutaneous AEs Associated With Improved Response and Survival in mRCC Treated With ICI/TKI Therapy
  4. Percutaneous Microwave Ablation of Renal Masses
  5. Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma After Nephrectomy
  6. No Association Between Soft Drink and Juice Consumption and RCC Incidence and Mortality
  7. Prognostic Impact of Loss of SETD2 in ccRCC
  8. Plasma KIM-1 Is Associated With Recurrence Risk After Nephrectomy for Localized Renal Cell Carcinoma
  9. Reduced Renal Function Does Not Predispose to Cancer-Specific Mortality From RCC
  10. Lenvatinib With or Without Everolimus in Patients With Metastatic RCC After ICI and VEGFR-TKI Therapies

Elsewhere

Recently Updated